Observational studyThe Journal of infectious diseases2020
Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City.
Observational study in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis.The lancet. Gastroenterology & hepatology · 2023Pooled it
- Correlates of Syringe Acquisition at Syringe Services Program and Pharmacies among Persons Who Inject Drugs: National HIV Behavioral Surveillance, United States, 2022.Journal of urban health : bulletin of the New York Academy of Medicine · 2026Article
- "How are we going to be able to pull that off?": staff perspectives on the early implementation of mobile medication units in New York State.Addiction science & clinical practice · 2026Article
- Sex differences in cancer incidence among people with HIV infection in the United States.Journal of the National Cancer Institute · 2026Article
- Care strategies for pregnant people and women living with hepatitis C in North America.AJOG global reports · 2026Article
- Potential impact of curative and preventive interventions toward hepatitis C elimination in people who inject drugs-A network modeling study.The International journal on drug policy · 2024Article
- The Urgent Need to Implement Point-of-Care RNA Testing for Hepatitis C Virus to Support Elimination.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Review
- Application of machine learning algorithms for localized syringe services program policy implementation - Florida, 2017.Annals of medicine · 2022Article
- The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures.Viruses · 2021Article
- Medicaid Subscription-Based Payment Models and Implications for Access to Hepatitis C Medications.JAMA health forum · 2021Article
- Care Facilitation Advances Movement Along the Hepatitis C Care Continuum for Persons With Human Immunodeficiency Virus, Hepatitis C, and Substance Use: A Randomized Clinical Trial (CTN-0064).Open forum infectious diseases · 2021Article
- Acceptability and Effectiveness of Hepatitis C Care at Syringe Service Programs for People Who Inject Drugs in New York City.Substance use & misuse · 2021Article
- Big Events theory and measures may help explain emerging long-term effects of current crises.Global public healthArticle
- Hepatitis C Treatment in Persons Who Inject Drugs in a Medication Assisted Treatment Program: A Retrospective Review of an Integrated Model.Journal of primary care & community healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundHepatitis C virus (HCV) incidence has increased in the worsening opioid epidemic. We examined the HCV preventive efficacy of medication-assisted treatment (MAT), and geographic variation in HCV community viral load (CVL) and its association with HCV incidence.
methodsHCV incidence was directly measured in an open cohort of patients in a MAT program in New York City between 1 January 2013 and 31 December 2016. Area-level HCV CVL was calculated. Associations of individual-level factors, and of HCV CVL, with HCV incidence were examined in separate analyses.
resultsAmong 8352 patients, HCV prevalence was 48.7%. Among 2535 patients seronegative at first antibody test, HCV incidence was 2.25/100 person-years of observation (PYO). Incidence was 6.70/100 PYO among those reporting main drug use by injection. Female gender, drug injection, and lower MAT retention were significantly associated with higher incidence rate ratios. Female gender, drug injection, and methadone doses <60 mg were independently associated with shorter time to HCV seroconversion. HCV CVLs varied significantly by geographic area.
conclusionsHCV incidence was higher among those with lower MAT retention and was lower among those receiving higher methadone doses, suggesting the need to ensure high MAT retention, adequate doses, and increased HCV prevention and treatment engagement. HCV CVLs vary geographically and merit further study as predictors of HCV incidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.